Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Expired activity Please go to the PowerPak homepage and select a course
1 Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a growing epidemic associated with metabolic disease ( Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including liraglutide, exenatide, semaglutide, beinaglutide, and dulaglutide, are commonly used in clinical practice to manage blood sugar and body weight
Most researchers anticipate that long-term treatment will be necessary to maintain results, similar to how blood pressure medication must be continued to maintain blood pressure control
Our study is likely to trigger a diversification of treatment options targeting GLP1R
This results in appetite suppression, increased alertness, elevated heart rate, and raised blood pressure
